03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Susanne Michel: no photograph is held, so the sector leader plate is shown instead.
Sector leader
Susanne Michel
Vice president, head of HTA methods and evidence planning, Clinigen
1
0
Oct 2026Nov 2026to date
1
press citation on 1 topic since 13 Oct 2026 · last quoted 13 Oct 2026
02 Quoted on · 1 of 29 topics
Susanne Michel: key facts
- Kind of voice
- Sector leader
- Role
- Vice president, head of HTA methods and evidence planning, Clinigen
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 13 Oct 2026
04 The signal · where Susanne Michel sits on rare diseases
Ranked 31= of 100 voices quoted in the press on rare diseases, level with 69 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1Giles LomaxSector leaderChief Executive Officer, Spinal Muscular Atrophy UK (SMA UK)5
- 2=
David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4 - 2=
Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4 - 31=Laura JohnsonClinicianLead Clinical Trials Midwife, University Hospitals of Derby and Burton1
- 31=Michael EpsteinSector leaderVice president, commercial strategy and pricing, Clinigen1
- 31=Susanne MichelSector leaderVice president, head of HTA methods and evidence planning, Clinigen1
- 31=Carmen BozicAcademicM.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex1
- 31=Chandrabali GhoseSector leaderChief scientific officer, Emily's Entourage1
Showing the leaders and the ranks around 31=, of 100 voices · See every voice on the topic →
05 On the record · press
What Susanne Michel has said
By outlet · linked articles
- bioxconomy.com1
Where Susanne Michel has been quoted
- 01MFN Pricing and the Future of Rare Disease Launchesbioxconomy.com · 13 Oct 2026
Verbatim
“Only orphan drugs launched with FDA approval and orphan designation and launching in Europe with orphan approval will be affected by MFN.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Rosie Huntington-Whiteley Wears The Backless Dress To End All Backless DressesVogue
- Husband and wife set up support group to help people live more positively with Motor Neurone DiseaseBlog Preston
- The British Ophthalmological Surveillance Unit: active surveillance of rare eye disease in the digital eraNature
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.